

DATE: March 1, 2007
Reference No. SASC07010

Via E-Mail

TO: PPTA North America Board
Peter O'Malley, Baxter BioScience
Bill Stopher, Grifols USA, Inc.
Flemming Nielsen, Octapharma USA, Inc.
Bill Zabel, Talecris Biotherapeutics
Robert Lefebvre, ZLB Behring

State Affairs Steering Committee
Valery Gallagher, Baxter Health Care
Michael Bradley, Baxter Health Care
Chris Healey, Grifols USA
Vlasta Prikazsky, Grifols USA
Stan Ammons, Octapharma
Jeff Lipe, Talecris Biotherapeutics
Ed Gdula, Talecris Biotherapeutics
Patrick Collins, ZLB Behring
Kim Isenberg, ZLB Behring

FROM: Ryan Faden, Assistant Director, State Affairs

CC: Julie Birkofer, Vice President, PPTA North America

SUBJECT: Outcome of the Arizona Senate Committee on Health Hearing

Urgent Handle & Confirm Review & Comment FYI As Requested

The purpose of this memorandum is to update you on the Arizona Senate Committee on Health hearing relating to Medicare access to IVIG. PPTA staff and member companies attended the hearing this morning. Dominick Spatafora (of the Neuropathy Action Foundation) introduced the panel of witnesses which included the mother of a consumer who utilizes IVIG, a physician treater, and a distributor. The primary message from the witnesses was that inadequate reimbursement in Medicare has resulted in impaired access to IVIG therapies. The primary outcome from the hearing is members of the Senate Committee on Health will draft a letter to the Arizona Congressional Delegation asking congress to take swift action in finding a solution to address the problems with access to IVIG.

Please feel free to contact the Association if you have any questions or need additional information regarding this issue.